Michael Byrne, Ph.D.Director of In vivo Biology and Ophthalmology at Wave Life Sciences
Dr. Byrne has been with Wave Life Sciences, Inc. for three years where he serves as director of in vivo biology and ophthalmology. In that time his focus has been on assessing the utility of stereopure oligonucleotides as potential therapeutics for rare inherited retinal diseases. Prior to joining Wave, Dr. Byrne spent 9 years at RXi Pharmaceuticals where he advanced RXi’s self-delivering siRNA oligonucleotides to the clinic for treatment of retinal scarring associated with late-stage AMD. Dr. Byrne received his Ph.D. from Northeastern University in Boston, MA where he studied microRNA expression patterns and impact on embryo development.